Several school based trials have been reported but although universal and targeted programmes can be efficacious, the results were mixed and the effects often modest.
An ongoing customized ERCC1-based chemotherapy trial has been designed based on this knowledge.
This correlation based reliability from trial to trial has been used by many other studies (e.g., [2, 8, 18]), and we would expect similar results for other correlation based measures.
The evidence based risk information studied in this trial has been developed and evaluated according to the UK Medical Research Council's framework for complex interventions.
Approval for the trial has been granted from the NHS Local Research Ethics Committee based at Saint James's University Hospital, Leeds.
The facility based trial had two PTs, one which was non-specific (psychoeducation) and one which was structured (IPT) and these were delivered in a collaborative stepped care format which included antidepressants.
Sample size calculations for the large trial have been based on an estimate of 20% infection in the saline control group[ 4].
Several subgroup analyses of the PROWESS trial have been performed based on clinical and biochemically relevant baseline variables.
Despite decreasing blood use, this latter study was not able to demonstrate a significant reduction in mortality - the primary endpoint - with rFVIIa use because the overall mortality in this entire cohort of severely injured patients was only 11%, and the trial had been powered based on the observed historical mortality of 25 to 30% in similarly injured patients [ 5].
However, there is frequently a set of variables whose relevance is unknown and for which data-dependent methods of selection, based on the data for the current trial, have been proposed.
